Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00522301
Other study ID # 07-080
Secondary ID P30CA008748MSKCC
Status Terminated
Phase Phase 2
First received August 28, 2007
Last updated February 1, 2016
Start date July 2007
Est. completion date March 2008

Study information

Verified date February 2016
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in at least the second remission.


Description:

OBJECTIVES:

Primary

- To determine the 12-month progression-free survival (PFS) rate of women with ovarian epithelial, fallopian tube, or peritoneal cancer in second or greater remission treated with oral sorafenib tosylate.

Secondary

- To determine the safety and tolerability of prolonged treatment with oral sorafenib tosylate in women with a history of recurrent ovarian cancer.

- To correlate serum markers of angiogenesis (i.e., VEGF and bFGF) and tumor markers pAKT, HIF-1 α , and VEGF with 12-month PFS.

OUTLINE: Patients receive oral sorafenib twice a day on days 1-28. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.

Patients undergo tumor tissue and blood sample collection at baseline, every 12 weeks during study, and after completion of study therapy for pharmacokinetic studies. Samples are analyzed for soluble markers of angiogenesis (i.e., VEGF and bFGF) via ELISA and HIF-1 α, VEGF, and pAKT via IHC staining.

After completion of study treatment, patients are followed at 4 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date March 2008
Est. primary completion date March 2008
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed epithelial carcinoma arising in the ovary, fallopian tube, or peritoneum

- Any stage and grade at diagnosis

- Must have received initial cytoreductive surgery and chemotherapy with = 1 platinum-based chemotherapy regimen

- Persistent or recurrent disease after initial therapy

- In complete clinical remission after chemotherapy for recurrent disease, meeting all of the following criteria:

- CA125 = 35 units/L

- Normal physical examination

- No definite evidence of disease by CT scan of the abdomen and pelvis

- Lymph nodes and/or soft tissue abnormalities = 1.0 cm are not considered definite evidence of disease

- No known brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

- Karnofsky performance status 70-100%

- Life expectancy > 3 months

- ANC = 1,500/mm³

- Platelet count = 100,000/mm³

- Hemoglobin = 9.0 g/dL

- INR < 1.5 OR PT/PTT within normal limits

- Creatinine = 1.5 times upper limit of normal (ULN)

- Urinalysis negative for protein

- If urinalysis shows 1+ protein by dipstick or protein = 30-100 mg/dL by semi-quantitative assay, a 24-hour urine collection is required

- Eligible patients must have a total urinary protein = 500 mg AND measured creatinine clearance = 50 mL/min from a 24-hour urine collection

- Bilirubin = 1.5 times ULN

- AST and ALT = 2.5 times ULN

- Alkaline phosphatase = 2.5 times ULN

- Stable blood pressure (BP) measurement required on 3 separate days prior to the start of treatment

- No peripheral neuropathy > grade 1

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

Exclusion criteria:

- Other invasive malignancies within the past 5 years, except nonmelanoma skin cancer

- Uncontrolled concurrent illness or medical condition including, but not limited to, any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Uncontrolled diabetes

- Psychiatric illness or social situation that would preclude study compliance

- Uncontrolled hypertension defined as a persistent BP > 150/100 mm Hg (or a persistent BP > 180/90 mm Hg if the patient has a history of isolated systolic hypertension) despite = 2 attempts at antihypertensive medication dosage adjustment = 2 weeks apart

- Thrombolic or embolic events such as cerebrovascular accident, including transient ischemic attack, within the past 6 months

- Pulmonary hemorrhage or bleeding event = grade 2 within 4 weeks of the first dose of study drug

- Other hemorrhage or bleeding event = grade 3 within 4 weeks of the first dose of study drug

- Serious nonhealing wound, ulcer, or bone fracture

- Evidence or history of bleeding diathesis or coagulopathy

- Inability to take oral medications or gastrointestinal condition that compromises absorption

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib tosylate

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

- See Disease Characteristics

- No prior sorafenib tosylate or other inhibitors of MAPK signaling intermediates or angiogenesis inhibitors

- No prior cancer treatment that would contraindicate protocol therapy

- More than 4 weeks since prior radiotherapy

- More than 3 weeks since prior chemotherapy, biological therapy, or immunotherapy

- More than 1 week since prior hormonal therapy for cancer treatment

Exclusion criteria:

- Major surgery (i.e., laparotomy) within the past 4 weeks or minor surgery within the past 2 weeks

- Placement of a vascular access device is not considered minor surgery

- Concurrent combination antiretroviral therapy for HIV-positive patients

- Concurrent St. John wort, rifampin, or enzyme-inducing anticonvulsants (e.g., carbamazepine, phenytoin, or phenobarbital)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
sorafenib tosylate

Other:
immunoenzyme technique

immunohistochemistry staining method

laboratory biomarker analysis

pharmacological study


Locations

Country Name City State
United States Memorial Sloan - Kettering Cancer Center New York New York

Sponsors (3)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Bayer, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (PFS) Rate at 12 Months All 5 patients experienced a rash. As a result, all 5 were either advised to withdraw from the protocol, or withdrew themselves from the protocol. The outcome was not met. 1 year No
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2